ATRC AtriCure, Inc.
AtriCure, Inc. (ATRC) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 22% planned / 78% discretionary
Largest single sale: $946.0K.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Privitera Salvatore | Chief Technical Officer | Sell 10b5-1 | 3,657 | $55.00 | $201.1K | 147,264 −2.4% of holding | |
| Privitera Salvatore | Chief Technical Officer | Sell 10b5-1 | 7,763 | $52.50 | $407.6K | 150,921 −4.9% of holding | |
| Dahlquist Karl S. | Chief Legal Officer | Sell | 9,370 | $48.89 | $458.1K | 87,319 −9.7% of holding | |
| Prange Karen | Director | Sell | 3,564 | $38.80 | $138.3K | 22,809 −13.5% of holding | |
| Yuen Maggie | Director | Sell | 3,500 | $38.42 | $134.5K | 14,015 −20% of holding | |
| Noznesky Justin J | Chief Mktg & Strategy Officer | Sell | 6,182 | $38.80 | $239.9K | 100,219 −5.8% of holding | |
| WEHRWEIN SVEN | Director | Sell | 25,000 | $37.84 | $946.0K | 40,518 −38.2% of holding | |
| Doraiswamy Vinayak | Chief Scientific Officer | Sell | 6,000 | $38.88 | $233.3K | 86,511 −6.5% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.